SCSara Cuadrado-Castano

Sara Cuadrado-Castano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sara Cuadrado-Castano has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In situ APMV-4 vaccination primes systemic response to subtherapeutic dosing of aCTLA-4 in colorectal carcinoma

    by Yonina Bykov, Natalia Alonso Moreda, Naseem Sadek, Gloria Dawodu, Srivatsan Swaminathan, Stephen T Yeung, Daniel Lozano Ojalvo, Javier De Las Rivas, Jeffrey A Tomalka, Adolfo García-Sastre, et al.

    Background: Colorectal carcinoma (CRC) is frequently typified by chronic inflammation and high levels of immunosuppression that render it resistant to immunotherapy. The multimodal immunostimulatory mechanisms of oncolytic virotherapy make it an attractive strategy for priming tumors for immune-checkpoint blockade (ICB). Here, we present an emerging oncolytic virotherapeutic, rAPMV-4, with previously described efficacy in preclinical models of CRC and melanoma. Methods: We expand on the established efficacy of APMV-4 by characterizing responses to the virotherapy in preclinical single and bilateral MicroSatellite Stable CRC tumor models. To investigate local and systemic effects of the virus, we characterized responses in tumors, draining lymph nodes, and sera using RNA-seq, high-dimensional flow cytometry, and cytokine analysis. Results: rAPMV-4 induced rapid, yet transient, interferon signaling, and early signatures of antigen presentation and T cell activation. Comparison with a human CRC cohort revealed a transcriptomic shift induced by the virus from a mesenchymal CMS4 to an “immune-high” CMS1 subtype predicted to respond well to ICB. Leveraging these signatures of response and resistance to the virotherapy, we designed a rational combinatorial approach with low-dose anti-CTLA-4, which reversed Treg activation and alleviated CD4 and CD8 dysfunction, leading to more potent systemic tumor elimination. Conclusions: This work supports the further clinical development of rAPMV-4, either alone or in combination, as an efficacious therapy for CRC.

  • Open Access

    Infectious bursal disease virus (IBDV) as a novel oncolytic virotherapy in glioblastoma

    by Vicent Tur-Planells, Yonina Bykov, Gloria Dawodu, Noemi García-Romero, Sara Izpura-Luis, Leticia Pérez-Rodríguez, Sergio Rius-Rocabert, Irina Palacín-Aliana, Javier Arranz-Herrero, Inmaculada Márquez-Leiva, et al.

    Background: Glioblastoma (GBM) is the most aggressive form of cancer of the central nervous system. Despite advances in immunotherapies and standard-of-care treatments for GBMs, clinical outcomes remain limited—owing to the immunosuppressive tumor microenvironment and the intrinsic resistance of GBM to conventional approaches. As a result, there is growing interest in rational combination strategies, particularly those pairing oncolytic viruses with immune-based therapies or established treatment modalities. Oncolytic viruses, by displaying conditionally enabled tumor cell-restricted replication, while stimulating antitumor immune responses and leaving healthy tissue unharmed, have the potential to reshape the therapeutic landscape in GBM and aid in achieving more durable benefits for patients. This study investigates the use of infectious bursal disease virus (IBDV) as a potential virotherapy for GBM. Methods and results: In vitro, IBDV infects and replicates within murine GBM cells and patient-derived GBM stem cells, inducing direct oncolysis and activating proinflammatory gene expression programs. IBDV also enhances the cytolytic activity of temozolomide (TMZ) in treated GBM cells, complementing TMZ chemotherapeutic activity. In vivo, treatment with IBDV in CT-2A GBM-bearing syngeneic mice significantly reduced tumor growth and improved survival compared with control mice. Intratumoral administration of IBDV induces a deep remodeling of the tumor immune microenvironment, reducing immunosuppressive M2-like macrophages and increasing the ratio of CD8+T cells to regulatory T cells. This reversion of immunosuppression linked to monocyte-derived macrophages has been confirmed on experimental ex vivo infections of explants derived from human GBM donors. Conclusion: These findings support further consideration of IBDV as a novel virotherapeutic agent for GBM.


  • Open Access

    Lymphangiogenesis driven by VEGF-C reshapes tumor immune landscape and enables tumor eradication by viral immunotherapy

    by Ruben Fernandez-Rodriguez, Sara Cuadrado-Castano, Andrew Edwards, Anita Rogic, Yonina Bykov, Ignacio Mena, Noelia Dasilva-Freire, Alice O Kamphorst, Rosa Karlic, Amir Horowitz, et al.

    Vascular Endothelial Growth Factor C (VEGF-C) is a key lymphangiogenic growth factor expressed by many types of cancer. Here, we investigated the effects of tumor-derived VEGF-C on the therapeutic efficacy of oncolytic virotherapy with avian paramyxoviruses APMV-1 (NDV) and AMPV-4. Treatment of B16F10 tumors not expressing VEGF-C with either virus led to tumor growth delay, and complete responses were rare. In contrast, when tumors expressed VEGF-C, viral therapy led to complete remission and long-term immunological memory in most mice. Upon re-challenge, most mice remained tumor- and metastasis-free for over 18 months, indicating durable immunity. VEGF-C induced tumor lymphangiogenesis, which correlated with high CD8 + and CD4 + T-cell densities in proximity of lymphatic vessels. Spectral flow cytometry revealed distinct changes in the composition and activation of CD8 + , CD4 + T cells and NK cells associated with complete remission. In responders, tumors were highly enriched in CD8 + CD25 + PD-1 + effector T cells. Composition of T cells was altered in sentinel and in contralateral lymph nodes, indicating a systemic immune response. Taken together, these data demonstrate VEGF-C-induced changes in tumor immune landscape which are critical for achieving complete response and support combining VEGF-C with APMV virotherapy as a novel highly effective strategy for cancer treatment.


  • Open Access

    Outcome of SARS-CoV-2 reinfection depends on genetic background in female mice

    by Gagandeep Singh, Juan García-Bernalt Diego, Prajakta Warang, Seok-Chan Park, Lauren A. Chang, Moataz Noureddine, Gabriel Laghlali, Yonina Bykov, Matthew Prellberg, Vivian Yan, et al.

    Antigenically distinct SARS-CoV-2 variants increase the reinfection risk for vaccinated and previously exposed population due to antibody neutralization escape. COVID-19 severity depends on many variables, including host immune responses, which differ depending on genetic predisposition. To address this, we perform immune profiling of female mice with different genetic backgrounds –transgenic K18-hACE2 and wild-type 129S1– infected with the severe B.1.351, 30 days after exposure to the milder BA.1 or severe H1N1. Prior BA.1 infection protects against B.1.351-induced morbidity in K18-hACE2 but aggravates disease in 129S1. H1N1 protects against B.1.351-induced morbidity only in 129S1. Enhanced severity in B.1.351 re-infected 129S1 is characterized by an increase of IL-10, IL-1β, IL-18 and IFN-γ, while in K18-hACE2 the cytokine profile resembles naïve mice undergoing their first viral infection. Enhanced pathology during 129S1 reinfection cannot be attributed to weaker adaptive immune responses to BA.1. Infection with BA.1 causes long-term differential remodeling and transcriptional changes in the bronchioalveolar CD11c+ compartment. K18-hACE2 CD11c+ cells show a strong antiviral defense expression profile whereas 129S1 CD11c+ cells present a more pro-inflammatory response upon restimulation. In conclusion, BA.1 induces cross-reactive adaptive immune responses in K18-hACE2 and 129S1, but reinfection outcome correlates with differential CD11c+ cells responses in the alveolar space.


  • Open Access

    Host immune responses associated with SARS-CoV-2 Omicron infection result in protection or pathology during reinfection depending on mouse genetic background.

    by Gagandeep Singh, Prajakta Warang, Juan García-Bernalt Diego, Lauren Chang, Yonina Bykov, Sarabjot Singh, Lars Pache, Sara Cuadrado-Castano, Brett Webb, Adolfo Garcia-Sastre, et al.

    Rapid emergence of antigenic distinct SARS-CoV-2 variants implies a greater risk of reinfection as viruses can escape neutralizing antibodies induced by vaccination or previous viral exposure. Disease severity during COVID-19 depends on many variables such as age-related comorbidities, host immune status and genetic variation. The host immune response during infection with SARS-CoV-2 may contribute to disease severity, which can range from asymptomatic to severe with fatal outcome. Furthermore, the extent of host immune response activation may rely on underlying genetic predisposition for disease or protection. To address these questions, we performed immune profiling studies in mice with different genetic backgrounds - transgenic K18-hACE2 and wild-type 129S1 mice – subjected to reinfection with the severe disease-causing SARS-CoV-2 B.1.351 variant, 30 days after experimental milder BA.1 infection. BA.1 preinfection conferred protection against B.1.351-induced morbidity in K18-hACE2 mice but aggravated disease in 129S1 mice. We found that he cytokine/chemokine profile in B.1.351 re-infected 129S1mice is similar to that during severe SARS-CoV-2 infection in humans and is characterized by a much higher level of IL-10, IL-1β, IL-18 and IFN-γ, whereas in B.1.351 re-infected K18-hACE2 mice, the cytokine profile echoes the signature of naïve mice undergoing viral infection for the first time. Interestingly, the enhanced pathology observed in 129S1 mice upon reinfection cannot be attributed to a less efficient induction of adaptive immune responses to the initial BA.1 infection, as both K18-hACE2 and 129S1 mice exhibited similar B and T cell responses at 30 DPI against BA.1, with similar anti-BA.1 or B.1.351 spike-specific ELISA binding titers, levels of germinal center B-cells, and SARS-CoV-2-Spike specific tissue-resident T-cells. Long-term effects of BA.1 infection are associated with differential transcriptional changes in bronchoalveolar lavage-derived CD11c + immune cells from K18-hACE2 and 129S1, with K18-hACE2 CD11c + cells showing a strong antiviral defense gene expression profile whereas 129S1 CD11c + cells showed a more pro-inflammatory response. In conclusion, initial infection with BA.1 induces cross-reactive adaptive immune responses in both K18-hACE2 and 129S1 mice, however the different disease outcome of reinfection seems to be driven by differential responses of CD11c + cells in the alveolar space.


  • Open Access

    Engineering Non-Human RNA Viruses for Cancer Therapy

    by Vicent Tur-Planells, Adolfo García-Sastre, Sara Cuadrado-Castano, Estanislao Nistal-Villan

    Alongside the development and progress in cancer immunotherapy, research in oncolytic viruses (OVs) continues advancing novel treatment strategies to the clinic. With almost 50 clinical trials carried out over the last decade, the opportunities for intervention using OVs are expanding beyond the old-fashioned concept of “lytic killers”, with promising breakthrough therapeutic strategies focused on leveraging the immunostimulatory potential of different viral platforms. This review presents an overview of non-human-adapted RNA viruses engineered for cancer therapy. Moreover, we describe the diverse strategies employed to manipulate the genomes of these viruses to optimize their therapeutic capabilities. By focusing on different aspects of this particular group of viruses, we describe the insights into the promising advancements in the field of virotherapy and its potential to revolutionize cancer treatment.


  • Open Access

    Supplementary Fig. S1 from Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models

    by Aryana Javaheri, Yonina Bykov, Ignacio Mena, Adolfo García-Sastre, Sara Cuadrado-Castano

    Antiviral response to APMV-4 and rAPMV-4 in normal cells.

  • Open Access

    Supplementary Fig. S1 from Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models

    by Aryana Javaheri, Yonina Bykov, Ignacio Mena, Adolfo García-Sastre, Sara Cuadrado-Castano

    Antiviral response to APMV-4 and rAPMV-4 in normal cells.